Long-term survival of glioblastoma multiforme: Importance of histopathological reevaluation

Journal of Neurology

Volumn 247, Issue 6, 2000, Pages 455-460

  Kraus, Jürgen A ^a   Wenghoefer, Matthias ^a   Schmidt, Matthias C ^a   Von Deimling, Andreas ^b   Berweiler, Ute ^c   Roggendorf, Wolfgang ^c   Diete, Sabine ^d   Dietzmann, Knut ^d   Müller, Bettina ^e   Heuser, Karlheinz ^f   Reifenberger, Guido ^a   Schlegel, Uwe ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e Klinik Bavaria in Kreischa GmbH   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Glioblastoma multiforme; Long term survival; Oligodendroglial differentiation

Indexed keywords

NITROSOUREA DERIVATIVE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER GRADING; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NERVE CELL DIFFERENTIATION; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CLASSIFICATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; BRAIN NEOPLASMS; DIAGNOSTIC ERRORS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 0033919618     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004150070175     Document Type: Article

References (29)

1. 1. Cairncross J, Macdonald DR, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer E (1994) Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013-2021
2. 2. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
3. 3. Chandler KL, Prados MD, Malec M, Wilson CB (1993) Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32:716-720
4. 4. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y (1983) Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperation Oncology Group study. Cancer 52:997-1007
5. 5. Coffey RJ, Lunsford LD, Taylor FH (1988) Survival after stereotactic biopsy of malignant gliomas. Neurosurgery 22:465-473
6. 6. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704-710
7. 7. DeAngelis LM, Burger PC, Green SB, Cairncross JG (1998) Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 44:691-695
8. 8. Devaux BC, O'Fallon JR, Kelly PJ (1993) Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 78:767-775
9. 9. Donahue B, Scott CB, Nelson JS, Rotman M, Murray KJ, Nelson DF, Banker FL, Earle JD, Fischbach JA, Asbell SO, Gaspar LE, Markoe AM, Curran W (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of radiation therapy oncology group 83-02. Int J Radiat Oncol Biol Phys 38:911-914
10. 10. Forsyth PA, Cairncross JG. Treatment of malignant glioma in adults (1995) Curr Opin Neurol 8:414-418
11. 11. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, Mealey J Jr, Odom GL, Paoletti P, Ransohoff J 2d, Robertson JT, Selker RG, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67:121-132
12. 12. Imperato JP, Paleologos NA, Vick NA (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28:818-822
13. 13. Jelsma R, Bucy PC (1969) Glioblastoma multiforme. Its treatment and some factors affecting survival. Arch Neurol 20:161-171
14. 14. Kim L, Hochberg FH, Thornton AF, Harsh GR, Patel H, Finkelstein D, Louis DN (1996) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and IV oligoastrocytomas. J Neurosurg 85:602-607
15. 15. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumors of the central nervous system. In: Kleihues P, Burger PC, Scheithauer BW (eds) International histological classification of tumors. World Health Organization, Geneva
16. 16. Lantos PL, VandenBerg SR, Kleihues P (1997) Tumours of the nervous system. In: Graham DI, Lantos PL (eds) Greenfield's neuropathology, 6th edn. Arnold, Edmonton, pp 600-626
17. 17. Morita M, Rosenblum MK, Bilsky MH, Fraser RAR, Rosenfeld MR (1996) Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics. J Neurooncol 27:259-266
18. 18. Olivera C, Bartley M, Ferrall S, Phuphanich S (1997) Long-term malignant glioma survivors over ten years: prognostic factors (abstract). Proceedings of ASCO 16:407a
19. 19. Salcman M, Scholtz H, Kaplan RS, Kulik S (1994) Long-term survival in patients with malignant astrocytoma. Neurosurgery 34:213-220
20. 20. Salford L, Brun A, Nirfalk S (1988) Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 69:506-550
21. 21. Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P (1998) Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci 25:197-201
22. 22. Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, van Gilder JC, Robertson JT, Ransohoff J, Mealey J, Strike TA, Pistenmaa DA (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 71:1-9
23. 23. Shaw EG, Scheithauer BW, O'Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428-434
24. 24. Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent Oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066-1073
25. 25. van den Bent MJ, Kros JM, Heimans JJ, Pronk LC, van Groeningen CJ, Krouwer HGJ, Taphoorn MJB, Zonnenberg BA, Tijssen CC, Twijnstra A, Punt CJA, Boogerd W (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51:1140-1145
26. 26. Vertosick FT, Selker RG (1992) Long-term survival after the diagnosis of malignant glioma: a series of 22 patients surviving more than 4 years after diagnosis. Surg Neurol 38:359-363
27. 27. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2d, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA (1980) Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329
28. 28. Wood JR, Green SB, Shapiro WR (1988) The prognostic importance of tumor size in malignant gliomas: a computerized tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6:338-343
29. 29. Zülch KJ (1979) Histological typing of tumors of the central nervous system. In: Zülch KJ (ed) International histological classification of tumors, no 21. World Health Organization, Geneva, pp 17-57